{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:37:17Z","timestamp":1793266637570,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012788","name":"Portland VA Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020523","name":"Drug Enforcement Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.105003","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:23:01Z","timestamp":1785799381000},"page":"105003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotype-dependent dissociation of binding affinity and functional potency in synthetic cannabinoids"],"prefix":"10.1016","volume":"393","author":[{"given":"Laura B.","family":"Kozell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-557X","authenticated-orcid":false,"given":"Amy J.","family":"Eshleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamryn A.","family":"Schutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley H.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-8845","authenticated-orcid":false,"given":"William E.","family":"Schutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Janowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheir I.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.105003_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2026.105003_bib2","series-title":"Understanding the \"Spice\" Phenomenon","year":"2009"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lfs.2013.09.026","article-title":"Emergence and properties of Spice and bath salts: a medicinal chemistry perspective","volume":"97","author":"Lewin","year":"2014","journal-title":"Life Sci"},{"issue":"1-2","key":"10.1016\/j.jpet.2026.105003_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","article-title":"Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample","volume":"131","author":"Winstock","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2026.105003_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112603","article-title":"Synthetic cannabinoid use among noninstitutionalized individuals in the United States, 2021\u20132023","volume":"270","author":"Palamar","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2026.105003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111613","article-title":"The identification of synthetic cannabinoids in English prisons","volume":"348","author":"Abbott","year":"2023","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.jpet.2026.105003_bib7","series-title":"New Psychoactive Substances in Prison","year":"2018"},{"issue":"12","key":"10.1016\/j.jpet.2026.105003_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.51951","article-title":"Identification and health risks of an emerging means of drug use in correctional facilities","volume":"7","author":"Kuai","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpet.2026.105003_bib9","series-title":"Center for Behavioral Health Statistics and Quality","first-page":"1","article-title":"Update: drug-related emergency department visits involving synthetic cannabinoids","author":"Bush","year":"2013"},{"issue":"2","key":"10.1016\/j.jpet.2026.105003_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N Engl J Med"},{"issue":"Pt A","key":"10.1016\/j.jpet.2026.105003_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2017.10.017","article-title":"Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112247","article-title":"Somatic and terminal CB1 receptors are differentially coupled to voltage-gated sodium channels in neocortical neurons","volume":"42","author":"Steiger","year":"2023","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2017.206","article-title":"CB1 receptor signaling in the brain: extracting specificity from ubiquity","volume":"43","author":"Busquets-Garcia","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/mol.65.3.665","article-title":"Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons","volume":"65","author":"Guo","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jpet.2026.105003_bib15","first-page":"327","article-title":"Effects of cannabinoids on neurotransmission","volume":"168","author":"Szabo","year":"2005"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/jpet.120.265561","article-title":"Fentanyl but not morphine interacts with nonopioid recombinant human neurotransmitter receptors and transporters","volume":"374","author":"Torralva","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"10.1016\/j.jpet.2026.105003_bib17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00213-014-3446-0","article-title":"Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro","volume":"231","author":"Janowsky","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2026.105003_bib18","first-page":"7577","article-title":"Schedules of controlled substances","volume":"79","year":"2014","journal-title":"Fed Regist"},{"key":"10.1016\/j.jpet.2026.105003_bib19","first-page":"5042","article-title":"Schedules of controlled substances","volume":"80","year":"2015","journal-title":"Fed Regist"},{"issue":"7","key":"10.1016\/j.jpet.2026.105003_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/dta.3037","volume":"13","author":"Pike","year":"2021","journal-title":"Drug Test Anal"},{"issue":"2","key":"10.1016\/j.jpet.2026.105003_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00204-025-04204-y","article-title":"Synthetic cannabinoid receptor agonists containing silicon: exploring the metabolic pathways of ADMB- and Cumyl-3TMS-PrINACA in human urine specimens and postmortem material compared to in vitro and in silico data","volume":"100","author":"Zschiesche","year":"2026","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","article-title":"Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids","volume":"97","author":"Wiley","year":"2014","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.jpet.2026.105003_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0376-8716(99)00152-0","article-title":"Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding","volume":"60","author":"Aung","year":"2000","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.jpet.2026.105003_bib24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/dta.3283","article-title":"Cannabinoid receptor activation potential of the next generation, generic ban-evading OXIZID synthetic cannabinoid receptor agonists","volume":"14","author":"Deventer","year":"2022","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jpet.2026.105003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176549","article-title":"Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists","volume":"971","author":"Patel","year":"2024","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2026.105003_bib26","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1007\/s00204-025-04191-0","article-title":"Outsmarting generic legislation: 4 years into the cat-and-mouse game of the synthetic cannabinoid receptor agonist market since the Chinese ban in 2021","volume":"99","author":"Deventer","year":"2025","journal-title":"Arch Toxicol"},{"issue":"21","key":"10.1016\/j.jpet.2026.105003_bib27","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1021\/acschemneuro.3c00530","article-title":"Subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor","volume":"14","author":"Yano","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/dta.3405","article-title":"Human phase I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F-EDMB-PICA and EDMB-PINACA","volume":"15","author":"Giorgetti","year":"2023","journal-title":"Drug Test Anal"},{"issue":"2","key":"10.1016\/j.jpet.2026.105003_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.jpet.2026.105003_bib30","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00204-025-04082-4","article-title":"In vitro CB1 receptor activity of halogenated indazole synthetic cannabinoid receptor agonists","volume":"99","author":"Green","year":"2025","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1021\/acschemneuro.2c00408","article-title":"Comprehensive characterization of a systematic library of alkyl and alicyclic synthetic cannabinoids related to CUMYL-PICA, CUMYL-BUTICA, CUMYL-CBMICA, and CUMYL-PINACA","volume":"14","author":"Janssens","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"10.1016\/j.jpet.2026.105003_bib32","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","article-title":"Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42238-026-00390-3","article-title":"Behavioral pharmacology of novel synthetic indazole, indole, and benzimidazole cannabinoids in rodents","volume":"8","author":"Shetty","year":"2026","journal-title":"J Cannabis Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.105003_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","article-title":"Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures","volume":"180","author":"Hua","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a signaling cannabinoid receptor 1-G protein complex","volume":"176","author":"Kumar","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jpet.2026.105003_bib36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2020.01.007","article-title":"Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex","volume":"180","author":"Xing","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jpet.2026.105003_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1039\/D1MD00242B","article-title":"Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA","volume":"13","author":"Sparkes","year":"2022","journal-title":"RSC Med Chem"},{"issue":"7","key":"10.1016\/j.jpet.2026.105003_bib39","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/dta.3035","volume":"13","author":"Grafinger","year":"2021","journal-title":"Drug Test Anal"},{"issue":"1","key":"10.1016\/j.jpet.2026.105003_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11419-017-0378-5","article-title":"Evaluation of carboxamide-type synthetic cannabinoids as CB1\/CB2 receptor agonists: difference between the enantiomers","volume":"36","author":"Doi","year":"2018","journal-title":"Forensic Toxicol"},{"key":"10.1016\/j.jpet.2026.105003_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fchem.2019.00321","article-title":"Enantiospecific synthesis, chiral separation, and biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor agonists and their detection in seized drug samples","volume":"7","author":"Antonides","year":"2019","journal-title":"Front Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.105003_bib42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.euroneuro.2018.10.004","article-title":"Spicing it up\u2014synthetic cannabinoid receptor agonists and psychosis: a systematic review","volume":"28","author":"Hobbs","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.jpet.2026.105003_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/appi.ajp.2011.11010176","article-title":"Psychosis associated with synthetic cannabinoid agonists: a case series","volume":"168","author":"Hurst","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2026.105003_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5811\/westjem.2016.2.29519","article-title":"Case series of synthetic cannabinoid intoxication from one toxicology center","volume":"17","author":"Katz","year":"2016","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.jpet.2026.105003_bib45","first-page":"191","article-title":"The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: evolution","volume":"252","author":"Banister","year":"2018"},{"issue":"9","key":"10.1016\/j.jpet.2026.105003_bib46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jat\/bkac002","article-title":"Synthetic cannabinoid receptor agonists in postmortem casework in Scotland","volume":"46","author":"Seywright","year":"2023","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.jpet.2026.105003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113871","article-title":"Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists","volume":"175","author":"Patel","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2026.105003_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116052","article-title":"Investigating selectivity and bias for G protein subtypes and \u03b2-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor","volume":"222","author":"Ryalls","year":"2024","journal-title":"Biochem Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:18:52Z","timestamp":1793265532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526012036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022356526012036"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105003","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotype-dependent dissociation of binding affinity and functional potency in synthetic cannabinoids","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"105003"}}